Experienced in Beta Thalassemia

Dr. Susan E. Prockop

Pediatric Hematology Oncology
300 Longwood Ave, 
Boston, MA 
32 Years of Experience
Experienced in Beta Thalassemia
300 Longwood Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Susan Prockop is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Prockop has been practicing medicine for over 32 years and is rated as an Experienced provider by MediFind in the treatment of Beta Thalassemia. Her top areas of expertise are Graft Versus Host Disease (GvHD), Severe Combined Immunodeficiency (SCID), Folliculitis, X-Linked Severe Combined Immunodeficiency, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 131 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles in the study of Beta Thalassemia.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in NY
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 4 Less Insurance Carriers -

Locations

300 Longwood Ave, Boston, MA 02115
Other Locations
450 Brookline Ave, Boston, MA 02215

Additional Areas of Focus

Dr. Prockop has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of JSP191 for Hematopoietic Cell Transplantation Conditioning to Achieve Engraftment and Immune Reconstitution in Subjects With SCID
Enrollment Status: Terminated
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drug: Humanized anti-CD117 Monoclonal Antibody
Study Phase: Phase 1/Phase 2
A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
A Phase II Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: October 17, 2024
Intervention Type: Biological
Study Drug: CMVpp65 Specific T-cells
Study Phase: Phase 2
An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases
An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune T-Lymphocytes Derived From a Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases
Enrollment Status: Completed
Publish Date: February 13, 2023
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
A Phase II Study of the Therapeutic Effects Of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies
Enrollment Status: Completed
Publish Date: October 21, 2022
Intervention Type: Biological
Study Phase: Phase 2
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
A Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Enrollment Status: Completed
Publish Date: March 17, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
A Phase II Trial of Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation
Enrollment Status: Completed
Publish Date: December 16, 2020
Intervention Type: Biological
Study Phase: Phase 2
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Analysis of Patients Treated for Wiskott-Aldrich Syndrome Since January 1, 1990 (RDCRN PIDTC-6904)
Enrollment Status: Completed
Publish Date: August 10, 2020
A Phase II Trial of EBV-Specific Cytotoxic T Cells for the Treatment of EBV Lymphomas or Other EBV-associated Malignancies
A Phase II Trial of EBV-Specific Cytotoxic T Cells for the Treatment of EBV Lymphomas or Other EBV-associated Malignancies
Enrollment Status: Withdrawn
Publish Date: June 11, 2020
Intervention Type: Biological
Study Phase: Phase 2
View 7 Less Clinical Trials

131 Total Publications

Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies.
Precision Editing of Cyclophilin A Generates Cyclosporine and Voclosporin Resistant Cellular Therapies.
Journal: bioRxiv : the preprint server for biology
Published: July 14, 2025
Similar Doctors
Distinguished in Beta Thalassemia
Dr. Daniel E. Bauer
Pediatric Hematology Oncology
Distinguished in Beta Thalassemia
Dr. Daniel E. Bauer
Pediatric Hematology Oncology
300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-355-7701
Languages Spoken:
English
See accepted insurances

Daniel Bauer is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Bauer is rated as a Distinguished provider by MediFind in the treatment of Beta Thalassemia. His top areas of expertise are NUT Carcinoma, Sickle Cell Disease, Beta Thalassemia, Hemoglobinopathy, and Bone Marrow Transplant.

Distinguished in Beta Thalassemia
Dr. Erica B. Esrick
Pediatric Hematology Oncology
Distinguished in Beta Thalassemia
Dr. Erica B. Esrick
Pediatric Hematology Oncology

Children's Hospital Pediatric Associates, Inc

300 Longwood Ave, 
Boston, MA 
 (0.1 miles away)
617-355-6000
Languages Spoken:
English
See accepted insurances

Erica Esrick is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Esrick is rated as a Distinguished provider by MediFind in the treatment of Beta Thalassemia. Her top areas of expertise are Sickle Cell Disease, Congenital Hemolytic Anemia, Hemolytic Anemia, and Beta Thalassemia.

Advanced in Beta Thalassemia
Dr. Vijay G. Sankaran
Pediatric Hematology Oncology
Advanced in Beta Thalassemia
Dr. Vijay G. Sankaran
Pediatric Hematology Oncology
450 Brookline Avenue, Dana-farber Cancer Institute, 
Boston, MA 
 (0.1 miles away)
617-355-6363
Languages Spoken:
English
See accepted insurances

Vijay Sankaran is a Pediatric Hematologist Oncology provider in Boston, Massachusetts. Dr. Sankaran is rated as a Distinguished provider by MediFind in the treatment of Beta Thalassemia. His top areas of expertise are Aase Syndrome, Pure Red Cell Aplasia, Anemia, Splenectomy, and Microvascular Decompression.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Prockop's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 30 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile